

Queen's University Belfast
School of Medicine, Dentistry and Biomedical Sciences
Centre for Cancer Research and Cell Biology

Haematology Research Group
References/Publications
July 2010 – August 2011

1. Barbui, T., Barosi, G., Birgegard, G., Cervantes, F., Finazzi, G., Griesshammer, M., Harrison, C., Hasselbalch, H.C., Hehlmann, R., Hoffman, R., Kiladjian, J.J., Kroger, N., Mesa, R., McMullin, M.F., Pardanani, A., Passamonti, F., Vannucchi, A.M., Reiter, A., Silver, R.T., Verstovsek, S., & Tefferi, A. (2011) Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. *J Clin Oncol*, **29**, 761-770.
2. Beer, P.A., Delhommeau, F., LeCouedic, J.P., Dawson, M.A., Chen, E., Bareford, D., Kusec, R., McMullin, M.F., Harrison, C.N., Vannucchi, A.M., Vainchenker, W., & Green, A.R. (2010) Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm. *Blood*, **115**, 2891-2900.
3. Bo Björkstrand, Simona Iacobelli, Ute Hegenbart, Astrid Gruber, Hildegard Greinix, Liisa Volin, Franco Narni, Pellegrino Musto, Meral Beksac, Alberto Bosi, Giuseppe Milone, Paolo Corradini, Hartmut Goldschmidt, Theo de Witte, Curly Morris, Dietger Niederwieser & Gösta Gahrton (2011) Tandem autologous/reduced-intensity allogeneic stem cell transplantation versus autologous transplantation in myeloma – long term follow up. *J Clin Onc.*, **29**, 3016-3022.
4. Burnett, A.K., Hills, R.K., Hunter, A., Milligan, D., Kell, J., Wheatley, K., Yin, J., McMullin, M.F., Cahalin, P., Craig, J., Bowen, D., & Russell, N. (2011) The addition of arsenic trioxide to low-dose Ara-C in older patients with AML does not improve outcome. *Leukemia*.
5. Burnett, A.K., Russell, N.H., Kell, J., Dennis, M., Milligan, D., Paolini, S., Yin, J., Culligan, D., Johnston, P., Murphy, J., McMullin, M.F., Hunter, A., Das-Gupta, E., Clark, R., Carr, R., & Hills, R.K. (2010b) European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy. *J.Clin.Oncol.*, **28**, 2389-2395.
6. Crawford, L.J., Peake, R., Price, S., Morris, T.C.M., & Irvine, A.E. (2010) Adiponectin is produced by lymphocytes and is a negative regulator of granulopoiesis. *J Leukoc Biol*, **88**, 807-811.
7. Crawford, L.J., Walker, B., & Irvine, A.E. (2011) Proteasome inhibitors in cancer therapy. *J Cell Commun.Signal*, **5**, 101-110
8. Cunniffe, G.M., Dickson, G.R., Partap, S., Stanton, K.T., & O'Brien, F.J. (2010) Development and characterisation of a collagen nano-hydroxyapatite composite scaffold for bone tissue engineering. *J.Mater.Sci.Mater.Med.*, **21**, 2293-2298.
9. Drain, S., Catherwood, M.A., & Denis, A.H. (2010a) Multidrug resistance in the chronic lymphoproliferative disorders. *Leuk.Lymphoma*.
10. Drain, S., Catherwood, M.A., & Denis, A.H. (2010b) Multidrug resistance in the chronic lymphoproliferative disorders. *Leuk Lymphoma*, **51**, 1793-1804.
11. Drain, S., Flannely, L., Drake, M.B., Kettle, P., Orr, N., Bjourson, A.J., Catherwood, M.A., & Alexander, H.D. (2011) Multidrug resistance gene expression and ABCB1 SNPs in plasma cell myeloma. *Leuk Res*.
12. Formenti, F., Beer, P.A., Croft, Q.P., Dorrington, K.L., Gale, D.P., Lappin, T.R., Lucas, G.S., Maher, E.R., Maxwell, P.H., McMullin, M.F., O'Connor, D.F., Percy, M.J., Pugh, C.W., Ratcliffe, P.J., Smith, T.G., Talbot, N.P., & Robbins, P.A. (2011) Cardiopulmonary function in two human disorders of the hypoxia-inducible factor (HIF) pathway: von Hippel-Lindau disease and HIF-2{alpha} gain-of-function mutation. *FASEB J*.

13. Foroni,L., Wilson,G., Gerrard,G., Mason,J., Grimwade,D., White,H.E., de Castro,D.G., Austin,S., Awan,A., Burt,E., Clench,T., Farruggia,J., Hancock,J., Irvine,A.E., Kizilors,A., Langabeer,S., Milner,B.J., Nickless,G., Schuh,A., Sproul,A., Wang,L., Wickham,C., & Cross,N.C.P. (2011a) Guidelines for the measurement of BCR-ABL1 transcripts in chronic myeloid leukaemia. *British Journal of Haematology*, **153**, 179-190
14. Foroni,L., Wilson,G., Gerrard,G., Mason,J., Grimwade,D., White,H.E., de Castro,D.G., Austin,S., Awan,A., Burt,E., Clench,T., Farruggia,J., Hancock,J., Irvine,A.E., Kizilors,A., Langabeer,S., Milner,B.J., Nickless,G., Schuh,A., Sproul,A., Wang,L., Wickham,C., & Cross,N.C. (2011b) Guidelines for the measurement of BCR-ABL1 transcripts in chronic myeloid leukaemia. *Br J Haematol*.
15. Goodyer,M.J., Elhassadi,E.I., Percy,M.J., & McMullin,M.F. (2011) A Novel Base Change Leading to Hb Vanderbilt [beta89(F5)Ser-->Arg, AGT>AGA]. *Hemoglobin*, **35**, 428-429.
16. Heaney,N.B., Pellicano,F., Zhang,B., Crawford,L., Chu,S., Kazmi,S.M., Allan,E.K., Jorgensen,H.G., Irvine,A.E., Bhatia,R., & Holyoake,T.L. (2010) Bortezomib induces apoptosis in primitive chronic myeloid leukemia cells including LTC-IC and NOD/SCID repopulating cells. *Blood*, **115**, 2241-2250.
17. Irvine A.E., Yeger H. and Perbal B. *Report on the Fifth International Workshop on the CCN Family of Genes*. In: CCN Proteins in Health and Disease. Pub Springer 2010; 5-13.
18. Jain,S., Harrison,C., McMullin,M.F., & Houston,R.F. (2010a) Tumour Lysis Syndrome after Splenic Irradiation in a Patient with JAK2 V617F Post-polycythaemia Vera Myelofibrosis. *Clin.Oncol.(R.Coll.Radiol.)*.
19. Jones,A.V., Campbell,P.J., Beer,P.A., Schnittger,S., Vannucchi,A.M., Zoi,K., Percy,M.J., McMullin,M.F., Scott,L.M., Tapper,W., Silver,R.T., Oscier,D., Harrison,C.N., Gallert,H., Kisialiou,A., Strike,P., Chase,A.J., Green,A.R., & Cross,N.C. (2010) The JAK2 46/1 haplotype predisposes to MPL-mutated myeloproliferative neoplasms. *Blood*, **115**, 4517-4523.
20. Kedward,A.L., McGalie,C., Venkatraman,L., Hamilton,J., El-Agnaf,M., & McKenna,K. (2010) Plasmacytoid dendritic cell neoplasm treated successfully with rituximab. *J.Eur.Acad.Dermatol.Venereol.*, **24**, 742-743.
21. Lappin,T. (2010) Dual control: the HIF-2 regulator. *Blood*, **116**, 2870-2871.
22. Lebert-Ghali,C.E., Fournier,M., Dickson,G.J., Thompson,A., Sauvageau,G., & Bijl,J.J. (2010) HoxA cluster is haploinsufficient for activity of hematopoietic stem and progenitor cells. *Exp Hematol*, **38**, 1074-1086.
23. Lee,F.S. & Percy,M.J. (2010) The HIF Pathway and Erythrocytosis. *Annu.Rev Pathol*.
24. Liggett,A., Crawford,L.J., Walker,B., Morris,T.C.M., & Irvine,A.E. (2010) Methods for measuring proteasome activity: current limitations and future developments. *Leuk Res*, **34**, 1403-1409.
25. Lopez,T.V., Lappin,T.R., Maxwell,P., Shi,Z., Lopez-Marure,R., Aguilar,C., & Rocha-Zavaleta,L. (2011) Autocrine/paracrine erythropoietin signalling promotes JAK/STAT-dependent proliferation of human cervical cancer cells. *Int J Cancer*.
26. Mc Callum L & Irvine A.E. (2010) *CCN3: A NOvel Growth Factor in Leukaemia*. In: CCN Proteins in Health and Disease. Pub Springer, 115-124
27. McCloskey,S. & McMullin,M.F. (2010) Snippets in haematology. *J Clin Pathol*, **63**, 1035-1039.
28. McMullin,M.F. (2010) HIF pathway mutations and erythrocytosis. *Expert.Rev Hematol.*, **3**, 93-101.
29. Morley,D., Selai,C., Schrag,A., Thompson,A.J., & Jahanshahi,M. (2010) Refinement and validation of the Parental Illness Impact Scale. *Parkinsonism.Relat Disord.*, **16**, 181-185.
30. Morris, TCM., Drake, M., Apperley, J., Iacobelli, S., Neiderwieser, D., van Biezen, A., Bjorkstrand, B. & Gahrton, G. (2010) Efficacy and outcome of autologous transplantation in rare myelomas. *Haematologica*, **31**(2), 119-131.
31. Curly Morris, Gordon Cook, Matthew Streetly, Paul Kettle, Mary Drake, Michael Quinn, Jim Cavet, Jane Tighe, Majit Kazmi, John Ashcroft, Mark Cook, John Snowden, Jane Conn,

- Heather Oakervee, Rakesh Popat, Jamie Cavenagh (2011) Re-transplantation after bortezomib based therapy. *Br J Haematol*, **135**, 666-668
32. Natoni,A., Murillo,L.S., Kliszczak,A.E., Catherwood,M.A., Montagnoli,A., Samali,A., O'Dwyer,M., & Santocanale,C. (2011) Mechanisms of action of a dual Cdc7/Cdk9 kinase inhibitor against quiescent and proliferating CLL cells. *Mol Cancer Ther*.
 33. Passamonti,F., Elena,C., Schnittger,S., Skoda,R.C., Green,A.R., Girodon,F., Kiladjian,J.J., McMullin,M.F., Ruggeri,M., Besses,C., Vannucchi,A.M., Lippert,E., Gisslinger,H., Rumi,E., Lehmann,T., Ortmann,C.A., Pietra,D., Pascutto,C., Haferlach,T., & Cazzola,M. (2011) Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. *Blood*, **117**, 2813-2816.
 34. Ravindranath,A., Yuen,H.F., Chan,K.K., Grills,C., Fennell,D.A., Lappin,T.R., & El-Tanani,M. (2011) Wnt-beta-catenin-Tcf-4 signalling-modulated invasiveness is dependent on osteopontin expression in breast cancer. *Br J Cancer*.
 35. Shi,Z., Hodges,V.M., Dunlop,E.A., Percy,M.J., Maxwell,A.P., El-Tanani,M., & Lappin,T.R. (2010) Erythropoietin-induced activation of the JAK2/STAT5, PI3K/Akt, and Ras/ERK pathways promotes malignant cell behavior in a modified breast cancer cell line. *Mol Cancer Res*, **8**, 615-626.
 36. Smalley,J.L., Gant,T.W., & Zhang,S.D. (2010) Application of connectivity mapping in predictive toxicology based on gene-expression similarity. *Toxicology*, **268**, 143-146.
 37. Stevenson,R., Fatehullah,A., Jagan,I., Deevi,R.K., Bingham,V., Irvine,A.E., Armstrong,M., Morrison,P.J., Dimmick,I., Stewart,R., & Campbell,F.C. (2011) Enhanced lymphocyte interferon (IFN)-gamma responses in a PTEN mutation-negative Cowden disease kindred. *Clin Exp Immunol*, **164**, 202-210.
 38. Stojkovic,M., Pittenger,M.F., Nolta,J.A., Lako,M., Lappin,T.R., & Murphy,M.J., Jr. (2010) STEM CELLS' Position Statement on hESC Research. *Stem Cells*.
 39. Suresh,S., McCallum,L., Lu,W., Lazar,N., Perbal,B., & Irvine,A.E. (2011) MicroRNAs 130a/b are regulated by BCR-ABL and downregulate expression of CCN3 in CML. *J Cell Commun.Signal*, **5**, 183-191.
 40. Tewari,P., Ryan,A.W., Hayden,P.J., Catherwood,M., Drain,S., Staines,A., Grant,T., Nieters,A., Becker,N., de,S.S., Foretova,L., Maynardie,M., Cocco,P., Boffetta,P., Brennan,P., Chanock,S., Lawler,M., & Browne,P.V. (2011) Genetic variation at the 8q24 locus confers risk to multiple myeloma. *Br J Haematol*.
 41. Theilgaard-Monch,K., Boulwood,J., Ferrari,S., Giannopoulos,K., Hernandez-Rivas,J.M., Kohlmann,A., Morgan,M., Porse,B., Tagliafico,E., Zwaan,C.M., Wainscoat,J., Van den Heuvel-Eibrink MM, Mills,K., & Bullinger,L. (2011) Gene expression profiling in MDS and AML: potential and future avenues. *Leukemia*.
 42. Twigg, S.M., Irvine, A.E., Leask, A., Perbal, B. *Report on the Sixth International Workshop on the CCN Family of Genes*. J Cell Commun Signal 2011
 43. Wheadon,H., Ramsey,J.M., Dobbin,E., Dickson,G.J., Corrigan,P.M., Freeburn,R.W., & Thompson,A. (2011) Differential Hox Expression in Murine Embryonic Stem Cell Models of Normal and Malignant Hematopoiesis. *Stem Cells Dev*.
 44. Yuen,H.F., Chan,Y.K., Grills,C., McCrudden,C.M., Gunasekharan,V., Shi,Z., Wong,A.S., Lappin,T.R., Chan,K.W., Fennell,D.A., Khoo,U.S., Johnston,P.G., & El-Tanani,M. (2011) Polyomavirus enhancer activator 3 protein promotes breast cancer metastatic progression through Snail-induced epithelial-mesenchymal transition. *J Pathol*, **224**, 78-89.